Welcome to our dedicated page for Applied Dna Scie SEC filings (Ticker: APDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The APDN SEC filings archive on Stock Titan provides access to the historical regulatory documents of Applied DNA Sciences, Inc., which has since changed its name to BNB Plus Corp. and its Nasdaq trading symbol to BNBX. These filings document the company’s evolution from a biotechnology issuer focused on PCR-based DNA technologies and nucleic acid production solutions to an issuer that also pursues a BNB-focused digital asset treasury strategy.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, including its LineaDNA, LineaRNAP, and LineaIVT platforms, segment information, and financial statements. Current reports on Form 8-K capture material events such as strategic restructurings, workforce reductions, the wind down of DNA tagging and security products and services, the cessation of Applied DNA Clinical Labs operations, reverse stock splits, private placement transactions, at-the-market offering agreements, and the initiation of the BNB-focused treasury strategy.
Filings also include proxy materials (DEF 14A) that describe proposals such as increasing authorized shares of common stock and amending the company’s equity incentive plan, along with information on corporate governance and executive compensation. Additional registration statements, including shelf registrations and related prospectus supplements, outline the company’s approaches to raising capital through equity offerings and warrant issuances.
On Stock Titan, these APDN filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as segment realignments, digital asset management agreements with Cypress LLC and Cypress Management LLC, and changes in corporate name and ticker symbol. Real-time connections to the SEC’s EDGAR system support timely updates as new filings are made under the company’s current identity, BNB Plus Corp. (BNBX). Users can also examine insider-related disclosures and warrant arrangements where reported, gaining a clearer view of historical capital structure and governance decisions linked to the former APDN symbol.
Applied DNA Sciences, Inc. implemented significant corporate and capital-structure actions in fiscal 2025 while restructuring operations to focus on Therapeutic DNA Production Services. The company completed two reverse stock splits (board-authorized 1-for-50 then 1-for-15, effective June 2, 2025) that adjusted warrant exercise prices and share counts. Since January 2025 the company has reduced headcount by 39%, expects a projected 31% reduction in payroll expenses versus fiscal 2024, and recorded approximately $305,000 and an additional $300,000 in one-time charges related to workforce reductions and ceasing ADCL operations; ADCL is accounted for as discontinued operations.
Revenue and receivables show high customer concentration (e.g., 26%, 23%, 12% in key segments; three customers represented 82% of accounts receivable at June 30, 2025). The company completed an October registered/direct offering with instruments priced at $240.00 (pre-funded warrants exercised during the period) and agreed to placement agent fees of 6% plus warrants. Lease and cash commitments include a $750,000 standby letter of credit and rent expense of $157,320 and $498,416 for the three- and nine-month periods ended June 30, 2025.